FDA-cleared profile

Vantage Galan 3T, MRT-3020, V9.0 with AiCE Reconstruction Processing Unit for MR

Canon Medical Systems Corporation · MRI · FDA-cleared (510(k))

Authorized purpose: The K230355 Vantage Galan 3T MR system with the MRT-3020 and V9.0 with AiCE Reconstruction Processing Unit acquires and reconstructs labeled diagnostic MR examinations on the compatible scanner configuration for qualified technologists and interpreting physicians.

Clinical role
Integrated MR reconstruction that accelerates acquisition or changes image appearance before routine professional interpretation.
Images and patients
MRI · Multi-region
Key limitation
Keep in mind: Performance depends on scanner, field strength, coil, sequence, anatomy, acceleration, input quality, and reconstruction setting; reconstructed images remain subject to physician review.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: The K230355 Vantage Galan 3T MR system with the MRT-3020 and V9.0 with AiCE Reconstruction Processing Unit acquires and reconstructs labeled diagnostic MR examinations on the compatible scanner configuration for qualified technologists and interpreting physicians.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Multi-region Input: Raw MRI acquisition data from supported scanners, coils, anatomies, pulse sequences, and acceleration settings.
  • Who uses it?Intended users: Qualified MRI technologists and interpreting physicians.
  • What does the software produce?Output: Reconstructed MR image series for professional review, export, and archival.
  • What is its most important limitation?Key limitation: Performance depends on scanner, field strength, coil, sequence, anatomy, acceleration, input quality, and reconstruction setting; reconstructed images remain subject to physician review.

Clinical takeaway. Clinical role: The K230355 Vantage Galan 3T MR system with the MRT-3020 and V9.0 with AiCE Reconstruction Processing Unit acquires and reconstructs labeled diagnostic MR examinations on the compatible scanner configuration for qualified technologists and interpreting physicians.

Evidence takeaway. Evidence from the reviewed source record: The K230355 FDA decision summary identifies the Vantage Galan 3T, MRT-3020, and V9.0 with AiCE Reconstruction Processing Unit and documents that the modification did not change the cleared intended use or indications. Software, image-quality, phantom, and system verification supports the release-specific reconstruction workflow; it does not establish a universal clinical sensitivity or specificity claim.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
The K230355 Vantage Galan 3T MR system with the MRT-3020 and V9.0 with AiCE Reconstruction Processing Unit acquires and reconstructs labeled diagnostic MR examinations on the compatible scanner configuration for qualified technologists and interpreting physicians.
  • Exact FDA submission
  • Checked 2026-09-03
Workflow role
Integrated MR reconstruction that accelerates acquisition or changes image appearance before routine professional interpretation.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Raw MRI acquisition data from supported scanners, coils, anatomies, pulse sequences, and acceleration settings.
  • Exact FDA submission
  • Checked 2026-09-03
Output and clinician action
Reconstructed MR image series for professional review, export, and archival.
  • Exact FDA submission
  • Checked 2026-09-03
Care setting
Hospital and outpatient MRI departments using compatible scanner models and release-specific sequences.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Qualified MRI technologists and interpreting physicians.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
Performance depends on scanner, field strength, coil, sequence, anatomy, acceleration, input quality, and reconstruction setting; reconstructed images remain subject to physician review.
  • Exact FDA submission
  • Checked 2026-09-03
Evidence summary
The K230355 FDA decision summary identifies the Vantage Galan 3T, MRT-3020, and V9.0 with AiCE Reconstruction Processing Unit and documents that the modification did not change the cleared intended use or indications. Software, image-quality, phantom, and system verification supports the release-specific reconstruction workflow; it does not establish a universal clinical sensitivity or specificity claim.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The K230355 FDA decision summary identifies the Vantage Galan 3T, MRT-3020, and V9.0 with AiCE Reconstruction Processing Unit and documents that the modification did not change the cleared intended use or indications. Software, image-quality, phantom, and system verification supports the release-specific reconstruction workflow; it does not establish a universal clinical sensitivity or specificity claim.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K230355 FDA performance package for Vantage Galan 3T, MRT-3020, V9.0 with AiCE Reconstruction Processing Unit for MR

  • DesignManufacturer MR hardware, AiCE reconstruction, software, image-quality, phantom, safety, EMC, and usability verification and validation submitted in K230355
  • PopulationRelease-specific Vantage Galan 3T MR acquisitions and reconstructed image series across the cleared anatomy, coils, sequences, and protocols
  • Scopeexact submission
  • Tested versionVantage Galan 3T, MRT-3020, V9.0 with AiCE Reconstruction Processing Unit (K230355)
  • IndependenceSponsor or vendor study

K230355

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
2 exact-submission FDA recall records in the 2026-09-02 openFDA snapshot identify K230355. Affected model, version, unit, correction, and current manufacturer instructions still require local confirmation. FDA recall Z-1017-2026 is Open, Classified for VANTAGE GALAN 3T Model MRT-3020/MEXL-3020. FDA reason: There is a potential for formation of ice occurring in the venting system of the superconducting magnet of the MRI systems. if a quench occurs in this condition, helium gas may not be able to escape via the designed vent paths, and the pressure in the helium vessel may rise. This pressure build-up could eventually rupture the helium vessel, causing helium gas to be released into the MR scanning room. FDA action: On 12/19/2025, the firm sent via Adobe DocuSign an "Urgent: Medical Device Correction" letter to customers informing them that It has been discovered that in the superconducting magnet used in the applicable system, if there is slow leakage, over a long period of time, of refrigerant gas from the superconducting magnet, air ingress into the helium vessel via the leak point may result in ice forming. If this is left unchecked, the worst-case scenario is that the helium gas will not be able to escape through the designed exhaust path, and the helium tank could eventually rupture, releasing helium gas into the MR scan room. For safety management of the superconducting magnet, the status of the magnet is checked during maintenance inspections and continuously monitored by a remote monitoring system. However, in response to the above report from the manufacturer of the superconducting magnet, an inspection to check for slow gas leaks in the superconducting magnet used in systems installed at our customer sites will be provided as a repair service. Note that there have been no reports of health hazards related to this incident. Customer are instructed to: The system can continue to be used. However, please ensure there are adequate evacuation routes from the scan/imaging room and the control room. Additionally, do not press the quench button in cases other than emergencies. A representative of Canon Medical Systems USA will contact you to schedule an inspection. If you have any questions regarding this matter, please contact your service representative. Share the contents of letter with all users and reviewing radiologist as well as clinical engineering or... FDA recall Z-2041-2024 is Open, Classified for MRI systems: Vantage Orian MRT-1550 (MEXL-1550), Vantage Elan MRT-2020 (MEXL-1520), Vantage Titan MRT-1504 (MEXL-1504), Vantage Titan 3T MRT-3010 (MEXL-3010), Vantage Galan 3T MRT-3020 (MEXL-3020). FDA reason: The terminal block used to secure the power supply cable for the gradient coil of the MRI system was not secured as designed, which could cause cable disconnection, which could lead to arcing, followed by melting of the cable, ignition, smoke, and fire. FDA action: On 5/10/24, correction notices were sent to customers who were asked to do the following: 1) The replacement of the power cable securing parts that may cause smoke and fire, with parts made of materials with a higher degree of flame retardance, is now being released. 2) A firm representative will contact you to schedule a time to replace the power cable securing parts. 3) If any abnormalities such as unusual smells or smoke are observed before the work, immediately stop using the system and contact your service representative. 4) The parts required to address the defect are expected to be available no earlier than June 2024. 5) Complete and return the reply form via DocuSign or via email to pbiggins@us.medical.canon For questions, please contact our InTouch team at intouchdispatch@us.medical.canon
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-1017-2026

Open, Classified

2026-01-13

Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.

recall: Z-2041-2024

Open, Classified

2024-06-09

Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; the FDA record does not identify an AI-algorithm defect unless it says so. Confirm affected model, version, units, corrective action, and completion status locally.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Raw MRI acquisition data from supported scanners, coils, anatomies, pulse sequences, and acceleration settings.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-03 · FDA 510(k) decision summary K230355: Vantage Galan 3T, MRT-3020, V9.0 with AiCE Reconstruction Processing Unit for MR

  2. Routing

    Source context, not route validation: Integrated scanner reconstruction followed by normal DICOM delivery; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.

    Scope: Product family. Current vendor materials are product-family evidence for K230355; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA 510(k) decision summary K230355: Vantage Galan 3T, MRT-3020, V9.0 with AiCE Reconstruction Processing Unit for MR · Canon Vantage Galan 3T

  3. AI processing

    Source context, not route validation: Licensed reconstruction software integrated into the specified MRI scanner configurations.

    Scope: Product family. Current vendor materials are product-family evidence for K230355; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA 510(k) decision summary K230355: Vantage Galan 3T, MRT-3020, V9.0 with AiCE Reconstruction Processing Unit for MR · Canon Vantage Galan 3T

  4. Returned objects

    Source context, not route validation: Reconstructed MR image series for professional review, export, and archival.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-03 · FDA 510(k) decision summary K230355: Vantage Galan 3T, MRT-3020, V9.0 with AiCE Reconstruction Processing Unit for MR

  5. Viewer/worklist/report

    Unresolved route: Reconstructed MR image series for professional review, export, and archival.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-03 · FDA 510(k) decision summary K230355: Vantage Galan 3T, MRT-3020, V9.0 with AiCE Reconstruction Processing Unit for MR

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Licensed reconstruction software integrated into the specified MRI scanner configurations.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K230355; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Integration
Integrated scanner reconstruction followed by normal DICOM delivery; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K230355; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Security
Canon Medical's cybersecurity page states that Canon imaging systems follow a software development life cycle governed by the NIST 800-53 Risk Management Framework adhering to Defense Health Agency certification requirements; FIPS 140-2 certified cipher standards; deny-all firewall configuration and near-real-time SIEM syslog export as premium offerings; a dedicated cybersecurity risk management team for threat intelligence monitoring, advisories and incident response; and published OS and third-party update policies. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the page is on us.medical.canon, Canon Medical's own site (Canon Medical Systems USA), and describes Canon Medical imaging devices generally; the FDA applicant is Canon Medical Systems Corporation, named in the corporate name-change press release on the same domain. Regional page with general device claims; exact-release scope is not established.

Training
Only qualified mri technologists and interpreting physicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Performance depends on scanner, field strength, coil, sequence, anatomy, acceleration, input quality, and reconstruction setting; reconstructed images remain subject to physician review.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K230355; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K230355 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Integrated scanner reconstruction followed by normal DICOM delivery; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.

product family · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Performance depends on scanner, field strength, coil, sequence, anatomy, acceleration, input quality, and reconstruction setting; reconstructed images remain subject to physician review.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Performance depends on scanner, field strength, coil, sequence, anatomy, acceleration, input quality, and reconstruction setting; reconstructed images remain subject to physician review.

product family · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
13Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. 2 FDA recall candidates were manually reviewed: 2 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 2 postmarket candidate records; 2 have been reviewed (2 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

10 sources - 3 history items

Source ledger

  1. FDA 510(k) decision summary K230355: Vantage Galan 3T, MRT-3020, V9.0 with AiCE Reconstruction Processing Unit for MR

    U.S. Food and Drug Administration - Published 2026-09-03 - Accessed 2026-09-03

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. FDA recall Z-1017-2026: VANTAGE GALAN 3T Model MRT-3020/MEXL-3020

    U.S. Food and Drug Administration - Published 2026-01-13 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  4. FDA recall Z-2041-2024: MRI systems: Vantage Orian MRT-1550 (MEXL-1550), Vantage Elan MRT-2020 (MEXL-1520), Vantage Titan MRT-1504 (MEXL-1504), Vantage Titan 3T MRT-3010 (MEXL-3010), Vantage Galan 3T MRT-3020 (MEXL-3020)

    U.S. Food and Drug Administration - Published 2024-06-09 - Accessed 2026-09-04

    Scope: postmarketSafety, affectedProduct, recallStatus, correctiveAction

  5. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  6. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  7. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  8. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  9. Canon Vantage Galan 3T

    Canon Medical Systems - Accessed 2026-09-03

    Scope: productFamilyContext, workflowRole, implementationCapabilities

  10. Canon Medical: Medical Imaging Cybersecurity

    Canon Medical Systems USA - Accessed 2026-10-26

    Scope: security

Research history

  1. K230355 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

Authorized purpose: S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and anatomy scope.

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252379

AIR Recon DL

Ge Medical Systems, LLC

Authorized purpose: AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or ringing and support image quality or scan-time choices.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-23
FDA-cleared K252838

MAGNETOM Sola; MAGNETOM Altea; MAGNETOM Sola Fit; MAGNETOM Viato.Mobile; MAGNETOM Vida; MAGNETOM Lumina; MAGNETOM Vida Fit; MAGNETOM Flow.Elite; MAGNETOM Flow.Neo; MAGNETOM Flow.Rise

Siemens Healthcare GmbH

Authorized purpose: The listed MAGNETOM 1.5T and 3T MRI systems produce cross-sectional images, spectroscopic images or spectra, and derived physical parameters of the head, body, and extremities for trained-physician interpretation and can support imaging during MR-compatible interventions.

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-19

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history